Terazosin

Base Information

• Chemical Name: Terazosin
• CAS No.: 63590-64-7
• Molecular Formula: C19H25N5O4
• Molecular Weight: 387.439
• European Community (EC) Number: 613-265-8
• UNII: 8L5014XET7
• DSSTox Substance ID: DTXSID3023639
• Nikkaji Number: J19.669J
• Wikipedia: Terazosin
• Wikidata: Q280786
• NCI Thesaurus Code: C61964
• RXCUI: 37798
• Pharos Ligand ID: BD967KAHXVAM
• Metabolomics Workbench ID: 43382
• ChEMBL ID: CHEMBL611
• Mol file: 63590-64-7.mol

Synonyms:A 45975;Adecur;Apo-Terazosin;Deflox;Dysalfa;Flotrin;Heitrin;Hytrin;Hytrin BPH;Hytrine;Magnurol;Novo-Terazosin;Nu-Terazosin;PMS-Terazosin;ratio-Terazosin;Sutif;Tazusin;Terazoflo;terazosin;Terazosin AZU;Terazosin Hexal;Terazosin hydrochloride;terazosin hydrochloride anhydrous;terazosin, monohydrochloride, dihydrate;Terazosina Alter;Terazosina Kern;Terazosina Qualix;Zayasel

Chemical Property of Terazosin

Chemical Property:

• Appearance/Colour: white to off-white crystalline powder
• Melting Point: 281-283 °C
• Boiling Point: 664.5 °C at 760 mmHg
• PKA: pKa (0.1N NaOH): 7.1(at 25℃)
• Flash Point: 355.7 °C
• PSA: 103.04000
• Density: 1.332 g/cm³
• LogP: 1.64090
• Storage Temp.: -20°C Freezer
• Solubility.: H2O: 25 mg/mL
• Water Solubility.: 30.6mg/L(22.5 oC)
• XLogP3: 1.4
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 8
• Rotatable Bond Count: 4
• Exact Mass: 387.19065430
• Heavy Atom Count: 28
• Complexity: 544

Purity/Quality:

99% ^*data from raw suppliers

Terazosin ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xn,Xi
• Hazard Codes: Xn,Xi
• Statements: 22-36/37/38
• Safety Statements: 26-36

MSDS Files:

SDS file from LookChem

Useful:

• Drug Classes: Antihypertensive Agents
• Canonical SMILES: COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC
• Recent ClinicalTrials: Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson's Patients
• Uses: Terazosin is used for the same indications as is prazosin; however, it has the advantage of being able to be used once a day. An a-1-adrenergicblocker related to prazosin
• Clinical Use: Alpha-adrenoceptor blocker: Hypertension Benign prostatic hyperplasia (BPH)
• Drug interactions: Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect. Antidepressants: enhanced hypotensive effect with MAOIs. Avanafil, vardenafil, sildenafil and tadalafil: enhanced hypotensive effect - avoid concomitant use. Beta-blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect. Calcium-channel blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect. Diuretics: enhanced hypotensive effect; increased risk of first dose hypotensive effect. Moxisylyte: possibly severe postural hypotension when used in combination.

Technology Process of Terazosin

There total 7 articles about Terazosin which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 90.9%

→ terazosin hydrochloride (141269-44-5) + terazosin (63590-64-7)

Guidance literature:

Reference yield: 65.0%

tetrahydro-2-furancarboxylic acid (16874-33-2) + 4-amino-6,7-dimethoxy-2-piperazin-1-ylquinazoline (60547-97-9) → terazosin (63590-64-7)

Guidance literature:

With N-ethyl-N,N-diisopropylamine; ethyl cyanoglyoxylate-2-oxime; In N,N-dimethyl-formamide; at 20 ℃;

DOI:10.1111/cbdd.12534

Reference yield:

1-(4-amino-6,7-dimethoxyquinazolin-2-yl)-4-[[(2RS)2,3,4,5-tetrahydrofuran-2-yl]carbonyl]piperazine hydrochloride hydrobromide (943644-21-1) → terazosin (63590-64-7)

Guidance literature:

With ammonia; In water; at 25 - 45 ℃; for 1h; pH=8.4;

upstream raw materials:

prazosin hydrochloride

2-chloro-6,7-dimethoxyquinazolin-4-amine

N-(tetrahydro-2-furoyl)-piperazine

1-(4-amino-6,7-dimethoxyquinazolin-2-yl)-4-[[(2RS)2,3,4,5-tetrahydrofuran-2-yl]carbonyl]piperazine hydrochloride hydrobromide

Refernces

• 1、 Bottini, Angel,De, Surya K.,Wu, Bainan,Tang, Changyan,Varani, Gabriele,Pellecchia, Maurizio. "Targeting Influenza A Virus RNA Promoter". . p. 663 - 673. Retrieved 2015/03/30.
• 2、 -. "ANTIHYPERTENSIVE THERAPY". . . Retrieved 2009/09/08.